Lookup NU author(s): Dr Andrew Gennery,
Professor Anne Dickinson,
Dr Gavin Spickett,
Dr Ann Curtis,
Professor Andrew Cant,
Dr Mario Abinun
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background SCID can be cured by BMT. Depletion of nature T cells from BM has enabled HLA non-identical stem-cell transplantation. We report the outcome of 30 patients treated with 37 T-cell depleted BMT procedures using CAMPATH-1M in vitro between 1987-98 in a single center. Methods Immune reconstitution and quality-of-life were assessed in 19 long-term survivors. All but two received pre-transplant conditioning. T- and B-cell chimerism, numbers and function were analyzed during a median follow-up of 5.3 years, (range 1.33-12). Results The overall engraftment rate was 59%, six children required repeated B-If T and the survival rate was 63%. All have donor T cells, 58% normal T-cell numbers and 74% normal T-cell function. Of 17 evaluated, 16 patients (94%) have normal IgM and IgG levels, and production of specific Abs to protein Ags, but only 5116 (31%) have a good response to pneumococcal polysaccharide. Early and late post-BMT complications were rare and there were no delayed deaths. Only one child continues on long-term i.v. Ig 4-years post-BAIT Eleven children died (37%). Discussion CAMPATH-1M T-cell depleted BMT for SCID resulted in 63% survival. Deaths of I I children were mainly due to pre-existing infections Seventeen of 19 long- term survivors have normal immune function and good quality-of-life.
Author(s): Cavanagh G; Dickinson AM; Curtis A; Abinun M; Cant AJ; Spickett GP; Gennery AR; Brigham K; Barge D; Spencer V; Jackson A; Carter V; Palmer P; Flood TJ
Publication type: Article
Publication status: Published
Print publication date: 01/01/2001
ISSN (print): 1465-3249
ISSN (electronic): 1477-2566
Publisher: Informa Healthcare
Altmetrics provided by Altmetric